Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Divests Business; Increases Share Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer said after the close of the market Tuesday that it has reached an agreement to sell its Illumination and Detection Solutions business to private equity group Veritas Capital Fund III for around $500 million in cash.

PerkinElmer said that the divestiture would enable it to reinvest in its core Human Health and Environmental Health businesses.

IDS is expected to bring in revenues of roughly $300 million for 2010. Its financial results will be reported as discontinued operations going forward. The unit employs around 3,000 people and makes specialty lighting and sensor components that are used in a variety of applications in the health, environmental, and security fields.

"The divestiture of our IDS business reduces the complexity of the company and frees up capital to reinvest in our more attractive Human Health and Environmental Health end markets," Robert Friel, chairman and CEO of PerkinElmer, said in a statement. "In addition, this transaction should reduce the company's exposure to more cyclical end markets and improve our top-line growth profile."

As a result of the divestiture, PerkinElmer has updated its 2010 financial guidance. The firm said that it now expects to report organic revenue growth in the high single digits and GAAP earnings per share of between $1.06 and $1.11. On an adjusted basis, its EPS is expected to be between $1.24 and $1.29, down from the forecast it provided in early August of between $1.49 and $1.54.

For full-year 2009, PerkinElmer had reported total revenues of $1.8 billion — with its Human Health segment bringing in revenues of $736.5 million and its Environmental Health segment generating sales of $1.08 billion. Its EPS for 2009 was $.73.

PerkinElmer also said that its board of directors had authorized an increase in the number of shares of the company's common stock available for repurchase to 13 million. It said that purchases would be made on the open market or through privately negotiated transactions.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.